Pioglitazone: A Better Choice of Drug in the Pre-diabetic Patients with High Risk of Cardiovascular Diseases
Manan B Dave*
Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana, Gujarat, India
- *Corresponding Author:
- Manan B Dave
Shri Sarvajanik Pharmacy College
Near Arvind Baug, Mehsana
E-mail: [email protected]
Received date: August 26, 2014; Accepted date: September 27, 2014; Published date: October 06, 2014
Citation: Dave MB (2014) Pioglitazone: A Better Choice of Drug in the Pre-diabetic Patients with High Risk of Cardiovascular Diseases. J Diabetes Metab 5:447. doi: 10.4172/2155-6156.1000447
Copyright: © 2014 Dave MB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Prediabetes is an intermediate condition between normal glycemia and clinical diabetes. Person with prediabetes condition have more chances of occurring diabetes and its associated cardiovascular disorder. Intervention of prediabetic person reduces its progression to diabetes and other cardiovascular diseases. Pioglitazone, a thiazolidinedione insulin sensitizer acts on peroxisome proliferator activated receptor and have a good response in diabetic condition. Apart from glycemic benefits it has anti-atherogenicity action that prevents the progression of cardiovascular disorder. These emerging effects of the drug pioglitazone on atherosclerosis warrant a better place in the management of diabetic patients with high risk of coronary artery disease.